US EditionUnlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins
Summary by digitaltwininsider.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Unlearn and remynd Partner on Alzheimer’s Study to Strengthen Confidence in Early Clinical Signals Using Digital Twins
SAN FRANCISCO & LEUVEN, Belgium–(BUSINESS WIRE)–Unlearn®, a leader in AI solutions for clinical trials, today announced results from a collaboration with remynd, a Belgium-based biotech company developing treatments for neurodegenerative diseases. The results were shared at the 2025 Alzheimer’s & Parkinson’s Drug Development Summit in Boston. The collaboration focused on remynd’s Phase 2a clinical trial of REM127, an investigational, first-gener…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
